0001562180-16-002781.txt : 20160707
0001562180-16-002781.hdr.sgml : 20160707
20160707160736
ACCESSION NUMBER: 0001562180-16-002781
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160706
FILED AS OF DATE: 20160707
DATE AS OF CHANGE: 20160707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nash Duane
CENTRAL INDEX KEY: 0001591098
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 161756682
MAIL ADDRESS:
STREET 1: C/O VITAL THERAPIES, INC.
STREET 2: 15010 AVENUE OF SCIENCE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92128
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2016-07-06
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001591098
Nash Duane
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET, SUITE 1100
CAMBRIDGE
MA
02142
true
false
false
false
Common Stock
2016-07-06
4
S
false
1980.00
7.4841
D
29629.00
D
47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date.
Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.38 to $7.60, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Nicole R. Hadas, Attorney-in-Fact for Duane Nash
2016-07-06